Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  BioPorto A/S    BIOPOR   DK0011048619

BIOPORTO A/S (BIOPOR)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompany 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
02/19/2018 02/20/2018 02/21/2018 02/22/2018 02/23/2018 Date
3.57(c) 3.535(c) 3.47(c) 3.45(c) 3.4(c) Last
161 318 34 398 124 145 118 449 168 272 Volume
-0.70% -0.98% -1.84% -0.58% -1.45% Change
More quotes
Company
Bioporto A/S is an in-vitro diagnostics company which provides healthcare professionals in clinical and research settings, a range of diagnostic tests and antibodies.It provides antibodies within medical specialties such as obesity, diabetes and primary immune deficiency.The company was founded on... 
Sector
Pharmaceuticals
Calendar
03/08Earnings Release
More about the company
Latest news on BIOPORTO A/S
02/10BIOPORTO A/S : and Roche Diagnostics sign a distribution agreement for NGAL
AQ
02/09BIOPORTO A/S : and Roche Diagnostics sign a distribution agreement for NGAL
AQ
01/16BIOPORTO A/S : Changes in the Board of Directors
AQ
01/04BIOPORTO A/S : Changes in the Board of Directors.
AQ
2017BIOPORTO A/S : Financial Calendar 2018
AQ
2017BIOPORTO A/S : USPTO approves BioPorto’s NGAL Trauma patent for issuance
AQ
2017BIOPORTO A/S : Share Capital and Votes
AQ
2017BIOPORTO A/S : Interim report, third quarter of 2017
AQ
2017BIOPORTO A/S : Managers’ transactions
AQ
2017BIOPORTO A/S : Completion of share capital increase
AQ
More news
Sector news : Diagnostic & Testing Substances Manufacturers
02/23PUMA BIOTECHNOLOGY : EU panel recommends against nod for Puma Biotech's breast c..
RE
02/23SANOFI : Says U.S. Waiting Period for Bioverativ Has Expired
DJ
02/23SHIRE : FDA to Conduct Priority Review of Shire Genetic-Disorder Drug
DJ
02/23NOVARTIS : Greek Parliament Approves Bribery and Price Fix Inquiry on Novartis -..
DJ
02/22NOVARTIS : Greek Parliament Investigates Politicians in Novartis Bribery Probe
DJ
More sector news : Diagnostic & Testing Substances Manufacturers
Latest Tweets
2017BioPorto A/S : Private placement fully subscribed  
2017BioPorto Release: First Patient Recruited For The NGAL Test Clinical Study In.. 
2017BioPorto A/S : First patient recruited for The NGAL Test™ clinical .. 
2017BioPorto A/S: BioPorto completes pre-submission discussions with the FDA #Fin.. 
2016BioPorto A/S: BioPorto expands its NGAL related patent portfolio #Finanzierun.. 
More tweets
Qtime:454
Chart BIOPORTO A/S
Duration : Period :
BioPorto A/S Technical Analysis Chart | BIOPOR | DK0011048619 | 4-Traders
Technical analysis trends BIOPORTO A/S
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Managers
NameTitle
Peter Mørch Eriksen Chief Executive Officer
Thomas Magnussen Chairman
Jan Kuhlmann Andersen Chief Operating Officer
Jakob Brix Christensen Chief Financial Officer
Torben A. Nielsen Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
BIOPORTO A/S4.23%0
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%224 221
PFIZER-1.33%213 155
ROCHE HOLDING LTD.-9.41%207 327
ABBVIE21.56%188 235